261 related articles for article (PubMed ID: 16684427)
21. Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.
Skroumpelos A; Agorastos T; Constantinidis T; Chatzistamatiou K; Kyriopoulos J
PLoS One; 2019; 14(12):e0226335. PubMed ID: 31830114
[TBL] [Abstract][Full Text] [Related]
22. Reducing the health burden of HPV infection through vaccination.
Soper D
Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
[TBL] [Abstract][Full Text] [Related]
23. Ambulatory care visits for Pap tests, abnormal Pap test results, and cervical cancer procedures in the United States.
Saraiya M; McCaig LF; Ekwueme DU
Am J Manag Care; 2010 Jun; 16(6):e137-44. PubMed ID: 20536271
[TBL] [Abstract][Full Text] [Related]
24. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
25. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
27. Genital warts incidence and healthcare resource utilisation in Australia.
Pirotta M; Stein AN; Conway EL; Harrison C; Britt H; Garland S
Sex Transm Infect; 2010 Jun; 86(3):181-6. PubMed ID: 19965802
[TBL] [Abstract][Full Text] [Related]
28. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
29. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods.
Layfield LJ; Qureshi MN
Diagn Cytopathol; 2005 Aug; 33(2):138-43. PubMed ID: 16007672
[TBL] [Abstract][Full Text] [Related]
30. Hospital resources consumed for surgical morbidity: effects of preoperative arginine and omega-3 fatty acid supplementation on costs.
Braga M; Gianotti L; Vignali A; Schmid A; Nespoli L; Di Carlo V
Nutrition; 2005; 21(11-12):1078-86. PubMed ID: 16308130
[TBL] [Abstract][Full Text] [Related]
31. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.
Giorgi Rossi P; Ricciardi A; Cohet C; Palazzo F; Furnari G; Valle S; Largeron N; Federici A
BMC Public Health; 2009 Feb; 9():71. PubMed ID: 19243586
[TBL] [Abstract][Full Text] [Related]
33. Use Trends and Recent Expenditures for Cervical Cancer Screening-Associated Services in Medicare Fee-for-Service Beneficiaries Older Than 65 Years.
Qin J; Holt HK; Richards TB; Saraiya M; Sawaya GF
JAMA Intern Med; 2023 Jan; 183(1):11-20. PubMed ID: 36409511
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
35. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
37. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
39. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
40. Assessing the short-term and long-term burden of illness in cervical cancer.
Lipsy RJ
Am J Manag Care; 2008 Jun; 14(6 Suppl 1):S177-84. PubMed ID: 18611085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
